About Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies is a company based in Hyderabad (India) founded in 2010 by M.S. Mohan and Hiren Patel. Orbicular Pharmaceutical Technologies has raised $20 million across 1 funding round from investors including Tata Capital Healthcare Fund. The company has 218 employees as of October 25, 2024. Orbicular Pharmaceutical Technologies offers products and services including Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations. Orbicular Pharmaceutical Technologies operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Hyderabad, India
- Employees 218 as on 25 Oct, 2024
- Founders M.S. Mohan, Hiren Patel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orbicular Pharmaceutical Technologies Private Limited
- Date of Incorporation 13 Aug, 2008
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$27.96 M (USD)0as on Mar 31, 2022
-
Net Profit
$10.98 M (USD)0as on Mar 31, 2022
-
EBITDA
$10.28 M (USD)0as on Mar 31, 2022
-
Total Equity Funding
$20 M (USD)
in 1 rounds
-
Latest Funding Round
$20 M (USD), Private Equity Round
May 31, 2024
- Investors
-
Employee Count
218
as on Oct 25, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies offers a comprehensive portfolio of products and services, including Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations.
Developed for niche generic pharmaceutical applications.
Formulations for skin and external drug delivery.
Specialty drugs for ocular treatments and applications.
Delivery systems for nasal medication administration.
Formulations for inhalation-based drug delivery.
Funding Insights of Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $20 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Tata Capital Healthcare Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund investing in healthcare and lifesciences in India.
|
Locked | Locked | Locked |
Investor details for Orbicular Pharmaceutical Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orbicular Pharmaceutical Technologies
Investment portfolio details for Orbicular Pharmaceutical Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orbicular Pharmaceutical Technologies
Detailed financials for Orbicular Pharmaceutical Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orbicular Pharmaceutical Technologies Comparisons
Peer comparison for Orbicular Pharmaceutical Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of Orbicular Pharmaceutical Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orbicular Pharmaceutical Technologies
Complete news archive for Orbicular Pharmaceutical Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies was founded in 2010 and raised its 1st funding round 14 years after it was founded.
Orbicular Pharmaceutical Technologies is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Orbicular Pharmaceutical Technologies is a funded company, having raised a total of $20M across 1 funding round to date.
As of Oct 25, 2024, the latest employee count at Orbicular Pharmaceutical Technologies is 218.
Annual revenue of Orbicular Pharmaceutical Technologies is $27.96M as on Mar 31, 2022.
Orbicular Pharmaceutical Technologies was established in 2010 and is based in Hyderabad, India. Operations focus on the pharmaceutical sector, where niche generic and specialty products are produced. These include injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalation formulations. Advanced technologies such as microspheres, nanosuspensions, nano-emulsions, liposomes, and peptides are utilized in manufacturing processes.
Orbicular Pharmaceutical Technologies's top competitors include Merck, Roivant Sciences and AbbVie.
Orbicular Pharmaceutical Technologies offers Complex Injectables, Topicals, Ophthalmics, Nasal Sprays, and Inhalations.
Orbicular Pharmaceutical Technologies has 1 investor. Key investors include Tata Capital Healthcare Fund.